Clinical Trials Logo

Clinical Trial Summary

The aim of this study is to identify different origin in carcinogenesis between serous borderline ovarian tumors presenting a. without implants, b. with non-invasive implants, c. with invasive implants and d. with micropapillary pattern. The presence of specific mutations could suggest for a more aggressive primary treatment if a higher risk of recurrence can be expected.


Clinical Trial Description

Introduction Borderline Ovarian Tumors (BOTs) behave indolently in the vast majority of cases and the prognosis is usually favorable. There is more evidence that two subtypes of BOTs represent a higher risk of recurrence or even progression to an invasive ovarian cancer. In case of a presentation with a micro-papillary grow pattern or when invasive implants are diagnosed the prognosis tend to be less favorable. Genome sequencing in ovarian cancer helped to differentiate two different pathways in the carcinogenesis. Low grade serous carcinomas evolving from adenofibromas or borderline tumors over non-invasive micropapillary serous borderline tumors to invasive micropapillary serous carcinoma, show frequent mutations in the Kirsten Rat Sarcoma gene (KRAS), B-Raf Kinase gene(BRAF), Erb-B2 Receptor Tyrosine Kinase 2 gene (ERBB2), Phosphatase and Tensin homolog gene (PTEN), Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha gene (PIK3CA) and Catenin Beta 1 gene (CTNNB1). This pathway is called Type I and is characterized by a slow step-wise process. These low-grade invasive tumors are indolent and are known with a better outcome than high-grade invasive tumors. In contrast the Type II pathway development of invasive tumors is rapid and vast majority of tumors show a Tumor Protein p53 (TP53) mutation and loss of Breast Cancer type 1 susceptibility protein (BRCA1). The aim of this study is to identify different origin in carcinogenesis between serous borderline ovarian tumors presenting a. without implants, b. with non-invasive implants, c. with invasive implants and d. with micropapillary pattern. The presence of specific mutations could suggest for a more aggressive primary treatment if a higher risk of recurrence can be expected. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03883542
Study type Observational
Source Universitair Ziekenhuis Brussel
Contact Stefan Cosyns, Dr
Phone 24776020
Email scosyns@uzbrussel.be
Status Recruiting
Phase
Start date January 2017
Completion date April 30, 2024

See also
  Status Clinical Trial Phase
Not yet recruiting NCT06466382 - OV Precision: Study Examining the Benefit of a Tumor- and Patient-specific Cancer Therapy N/A
Recruiting NCT05001282 - A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRĪ±) Phase 1/Phase 2
Recruiting NCT05960630 - MIRRORS-RCT Pilot: Role of Robotic Interval Cytoreductive Surgery for Advanced Ovarian Cancer N/A
Recruiting NCT04111978 - MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO) Phase 3
Recruiting NCT03509246 - Bortezomib and Pegylated Liposomal Doxorubicin in BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer Patients Phase 2
Recruiting NCT04402333 - Minimally Invasive Robotic Surgery, Role in Optimal Debulking Ovarian Cancer, Recovery & Survival
Recruiting NCT04780945 - Functional Analysis of BRCAness Phase 2
Recruiting NCT03015376 - Inherited Susceptible Genes Among Epithelial Ovarian Cancer
Completed NCT06103214 - The Effects of Hemodilution Methods in Patients Undergoing Primary Debulking Gynaecological Surgery N/A
Recruiting NCT05605535 - Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Phase 2